Key Drivers
- Strong liquidity
- High gross margins
- Large operating spend
AIAI Summary
ARQT has transitioned from a binary clinical-stage biotech into a cash-flowing specialty pharma where ZORYVE commercial execution and margin sustainability now matter as much as pipeline outcomes. The key opportunity is pediatric sNDA-driven market expansion, but single-product concentration, payer/supply risks and rich valuation mean overweight only with consecutive quarters of predictable revenue, gross-margin stability, and positive operating cash flow.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross margins
- •Large operating spend
ARQT has strong liquidity and very high gross margins but faces large, volatile operating losses and an outsized valuation that make the recent profitable quarter encouraging yet insufficient to offset material earnings and valuation risk.
Price Behavior
Key Price Behavior Insights:
- •Downtrend persist
- •Trading at lows
- •Elevated volatility
ARQT is in a clear short-term downtrend over the last month (≈ −12.5%), trading at recent lows that mark $22.24 support and near-term resistance around $24.6–$24.8 (with stronger resistance $26.9–$28.6) amid elevated short-term volatility.
Rapid decline from late‑February highs to
Sentiment & News
Key News Insights:
- •Strong sales
- •Profitability shift
- •Pipeline progress
Arcutis crushed Q4 with $127.5M ZORYVE sales, turned GAAP profitable, raised 2026 guidance and signaled sustainable positive cash flow while advancing pediatric/first‑in‑human clinical programs and expanding commercialization.
The results and guidance upgrade materially de‑risk the commercial story, supporting a premium valuation as sales momentum and upcoming regulatory/clinical catalysts reduce execution risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings